Australian Clinical Labs Limited (ASX:ACL)
Australia flag Australia · Delayed Price · Currency is AUD
3.320
-0.030 (-0.90%)
Nov 17, 2026, 11:19 AM AEDT

Australian Clinical Labs Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Australian Clinical Labs stock has a consensus rating of "Hold" and an average price target of $2.95. The average 1-year stock price forecast is 11.14% lower than the current stock price, while the lowest is $2.40 (-27.71%) and the highest is $3.65 (+9.94%).

Price Target: $2.95 (-11.14%)
Analyst Consensus: Hold

Price Target

Chart
TargetLowAverageMedianHigh
Price$2.40$2.95$2.90$3.65
Change-27.71%-11.14%-12.65%+9.94%

Analyst Ratings

The average analyst rating for Australian Clinical Labs stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Chart
RatingMay '26Jun '26Jul '26Aug '26Sep '26Oct '26
Strong Buy222322
Buy000000
Hold666444
Sell000000
Strong Sell000111
Total888877

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Ord Minnett
Ord Minnett
Hold
Maintains
$2.60 → $3.00
HoldMaintains$2.60 → $3.00-9.64%Oct 30, 2026
Unknown Analyst
Macquarie
No rating
Macquarie
Hold
Maintains
$2.70 → $2.90
HoldMaintains$2.70 → $2.90-12.65%Oct 28, 2026
RBC Capital
RBC Capital
Hold
Maintains
$2.40 → $2.75
HoldMaintains$2.40 → $2.75-17.17%Oct 28, 2026
Goldman Sachs
Goldman Sachs
Sell
Downgrades
$2.25 → $2.08
SellDowngrades$2.25 → $2.08-37.35%Aug 7, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
757.42M
from 736.15M
Increased by 2.89%
Revenue Next Year
787.88M
from 757.42M
Increased by 4.02%
EPS This Year
0.19
from 0.18
Increased by 5.24%
EPS Next Year
0.21
from 0.19
Increased by 8.98%
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingJun 30, 2022Jun 30, 2023Jun 30, 2024Jun 30, 2025Jun 30, 2026Jun 30, 2027
Revenue
995.60M697.07M696.37M741.27M736.15M757.42M
Revenue Growth
53.95%-29.99%-0.10%6.45%-0.69%2.89%
Gross Profit
448.62M251.62M254.00M280.93M280.68M301.45M
Gross Margin
45.06%36.10%36.47%37.90%38.13%39.80%
Operating Income
273.98M65.22M62.55M68.00M69.56M71.53M
Net Income
178.24M35.90M23.93M32.43M23.71M36.10M
EPS
----0.180.19
EPS Growth
----3.39%5.24%
Forward PE
9.6415.9213.8313.9412.6617.26
Dividend / Share
0.530.140.120.130.130.14
Dividend Growth
271.93%-73.59%-14.29%4.17%4.00%9.82%
Free Cash Flow
----153.73M158.05M
No. Analysts
-----7
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is AUD.

Revenue Forecast

Revenue202720282029
High762.3M
Avg757.4M
Low753.9M

Revenue Growth

Revenue Growth202720282029
High
3.6%
Avg
2.9%
Low
2.4%

EPS Forecast

EPS202720282029
High0.20
Avg0.19
Low0.19

EPS Growth

EPS Growth202720282029
High
8.9%
Avg
5.2%
Low
3.9%